BioTroy Therapeutics
Latest round
- Series A
Last raised
- Jun 2025
Total raised
- Undisclosed
Investors
- 6
About BioTroy Therapeutics
Established in 2020 and based in Shanghai, China, BioTroy Therapeutics has built BioTroy Engine, an integrated platform for new tumor immune target discovery. Jie Xu, the founder of the company, has studied and discovered new pathway regulation mechanisms such as PD-1/PD-L1, p53, MAPK, NFKB, WNT, and RhoGAP. The company has completed platform construction for target biology, antibody discovery and upstream process development, and based on the BioTroy Engine, the company has identified a series of first-in-class IO targets including BT1 and BT2, which can be enabled advanced level of immunosuppression against lung cancer, breast cancer, colorectal cancer and other high incidence of solid tumors. And also, the company has identified four receptors that can be bound by the BT1 target, by developing monoclonal antibodies against BT1 targets, we can effectively block the binding of BT1 targets and downstream receptors, thereby relieving the inhibition of BT1 on T cells and inhibiting the production of Treg and MDSC, can bring a solution to the current clinical PD-(L)1 ineffective and drug-resistant people.
Who invested in BioTroy Therapeutics
6 investors across 2 rounds
See all investors in BioTroy Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BioTroy Therapeutics
Who invested in BioTroy Therapeutics?
BioTroy Therapeutics has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BioTroy Therapeutics raised?
BioTroy Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did BioTroy Therapeutics last raise money?
BioTroy Therapeutics's most recent round on record is a Series A, in Jun 2025.
What does BioTroy Therapeutics do?
Established in 2020 and based in Shanghai, China, BioTroy Therapeutics has built BioTroy Engine, an integrated platform for new tumor immune target discovery.
Where is BioTroy Therapeutics headquartered?
BioTroy Therapeutics is headquartered in Shanghai, China.
Which VCs invest in companies like BioTroy Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at BioTroy Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like BioTroy Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.